Therapeutic dose of nebivolol, a nitric oxide-releasing β-blocker, reduces atherosclerosis in cholesterol-fed rabbits

This publication has 46 references indexed in Scilit:

• Use of Nebivolol For the Treatment of Endothelial Dysfunction in Patients With Hypertension: The EDEN Registry
  Journal of Cardiovascular Pharmacology, 2008
• Efficacy and Tolerability of Nebivolol Compared with Other Antihypertensive Drugs
  American Journal of Cardiovascular Drugs, 2008
• Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis
  Free Radical Biology and Medicine, 2007
• Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: Data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial
  American Heart Journal, 2007
• Nebivolol Increases Arterial Distensibility In Vivo
  Hypertension, 2004
• Nitric Oxide–Releasing Drugs
  Annual Review of Pharmacology and Toxicology, 2003
• Mildly Oxidized Low-Density Lipoprotein Impairs Responses of Carotid but Not Basilar Artery in Rabbits
  Stroke, 1997
• Carvedilol Inhibits Aortic Lipid Deposition in the Hypercholesterolemic Rat
  Pharmacology, 1997
• Effect of vitamin E on atherogenesis in LDL receptor-deficient rabbits
  Atherosclerosis, 1995
• Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits
  Atherosclerosis, 1992